Article Text

PDF
P110 Neurofibromatosis type 1 and von hippel-lindau disease: a possible association
  1. Clementina Calabrese2,
  2. Lucia Soldano2,
  3. Carmela De Meco1,
  4. Pasquale Pio Maccarone1,
  5. Luciana Romaniello2,
  6. Salvatore Cringoli2,
  7. Angela Maggio3,
  8. Anna Lanzano2,
  9. Michele Sacco1,
  10. Pettoello- Mantovani2
  1. 1Department of Paediatrics, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
  2. 3Departement of Paediatric Onco-Haematology, IRCCS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
  3. 2Institute of Paediatrics of the University of Foggia, Italy

Abstract

Case report L.F., 11 year old boy with neurofibromatosis type 1 (NF1), was admitted to our Clinic for headache. During hospitalisation were performed: 24 hour blood pressure monitor documenting isolated systolic hypertension grade I, Doppler ultrasound of renal vessels which diagnosis of the left renal artery severe stenosis (confirmed at angiography) and MRI brain highlighting extra-axial lesion (1.2 cm) in posterior cranial fossa (PCF). Nifedipine (10 mg/day) therapy was started, and subsequently intravascular stent was placed in renal artery. Neuroradiological control (MRI) showed increased in brain lesion (>2 cm). Surgical removal and histological evaluation allowed diagnosis of hemangioblastoma, with diagnostic suspicion for Von Hipple Lindau syndrome (VHL), confirmed by genetic analysis.

Conclusions NF1 is an autosomal dominant, multisystemic and progressive disease, with multiple complications. These include high blood pressure, described in 6% of patients, mostly caused by renal artery stenosis, pheochromocytoma or coarctation of aorta. The hemangioblastoma, however, is the most characteristic lesion of VHL disease. In literature it has been reported association between VHL-NF1: both diseases are part of neurocutaneous syndromes and it is possible to hypothesise a common dysplastic origin.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.